Early tacrolimus + prednisolone + nintedanib therapy markedly improved the forced vital capacity decline slope from –20.9% to +11.2% per year in untreated PPF. Initiating combination therapy with ...

The prevalence of type 2 diabetes in patients with autoimmune liver disease was 27.6%. Type 2 diabetes seems to reduce the risk of primary sclerosing cholangitis (PSC), and primary biliary cholangitis ...

Three of the 4 patients with hereditary transthyretin amyloidosis (ATTR) and a negative bone scintigraphy had cardiac carbon-11-labeled Pittsburgh compound B uptake. Cardiomyopathy could be detected ...

No matter if I ate healthy, went to yoga, drank water, and did all the necessary things, the weight started to pile on. I am someone who has struggled with my weight my entire life. I’ve done the ...

Agreement between the FaRL-based model and human experts was high for true negatives (86%) but lower for true positives (60%). A machine learning model trained specifically on human faces can detect ...

Participants taking 18 mg of nerandomilast experienced a significantly lower risk of acute exacerbation of interstitial lung disease. The US Food and Drug Administration (FDA) has approved ...

Multiomics integration identified 31 candidate genes that may underlie early decitabine resistance and suggest sensitization strategies. To enable comparable cytotoxicity, optimized conditions were ...

The researchers reported that Scheuer stage score increased significantly with histological stage and GLOBE score. The GLOBE score of patients with primary biliary cholangitis (PBC) before treatment ...

Living with HAE means constant self-education, including connecting with patient groups across social media platforms to share experiences, insights, and lessons learned. As someone living with ...

Patients diagnosed with CIDP who were positive for anti-Caspr1 IgG4-associated autoimmune nodopathy were mostly male and older at the time of disease onset. Immunoglobulin G4 contactin–associated ...

The authors used individual patient data from garadacimab trials (phase 2 and 3 VANGUARD) and published summary data from the phase 3 HELP trial for lanadelumab. Garadacimab may offer superior ...

No participant in the study developed FIX inhibitors, experienced thrombosis, recurrent liver enzyme elevations, or died during the follow-up period. A single intravenous infusion of the ...